Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM6B | O15054 | 1/20 | 0.40 |
| ▸ | KDM5C | P41229 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.40 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16796251 | 0.81 | KMT2A (0.47) | KDM4EALDH1A1NPSR1HTT | |
| SCHEMBL7077382 | 0.79 | KMT2A (0.43) | KDM4EL3MBTL1ALDH1A1KDM6BKDM5C | |
| SCHEMBL165741 | 0.79 | KDM4E (0.41) | KDM4EL3MBTL1ALDH1A1KDM6BKDM5C | |
| SCHEMBL8159378 | 0.79 | SORD (0.44) | ALDH1A1KMO | |
| SCHEMBL351032 | 0.78 | KDM4E (0.40) | KDM4EL3MBTL1ALDH1A1KDM6BKDM5C | |
| SCHEMBL3714129 | 0.78 | ROCK1 (0.44) | KDM4EL3MBTL1ALDH1A1KDM6BKDM5C | |
| SCHEMBL2762628 | 0.78 | KDM4E (0.40) | KDM4EL3MBTL1ALDH1A1KDM6BKDM5C | |
| SCHEMBL282078 | 0.78 | L3MBTL1 (0.38) | KDM4EL3MBTL1KMOALOX15 | |
| SCHEMBL31344571 | 0.78 | ALDH1A1 (0.47) | KDM4EL3MBTL1ALDH1A1KDM6BKDM5C | |
| SCHEMBL7373737 | 0.77 | KDM4E (0.38) | KDM4EL3MBTL1ALDH1A1KDM6BKDM5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4225762-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12612416-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-04-28 | — | — | US | disclosed |
| EP-3877366-B1 | NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-01-28 | — | — | EP | disclosed |
| WO-2025215110-A1 | NEW AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS SOS1 INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2025-10-16 | — | — | WO | disclosed |
| US-20250179079-A1 | HEXAHYDROPYRIDO[4,3-B]INDOLYL KETONE DERIVATIVES USEFUL AS CGAS MODULATORS | VENTUS THERAPEUTICS U.S., INC. (US) | 2025-06-05 | — | — | US | disclosed |
| WO-2025076284-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | DELPHIA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250074895-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION | 2025-03-06 | — | — | US | disclosed |
| EP-4496796-A1 | HEXAHYDROPYRIDO[4,3-B]INDOLYL KETONE DERIVATIVES USEFUL AS CGAS MODULATORS | Ventus Therapeutics U.S., Inc. (US) | 2025-01-29 | — | — | EP | disclosed |
| EP-4433470-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | Blueprint Medicines Corporation (US) | 2024-09-25 | — | — | EP | disclosed |
| US-12065438-B2 | Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-08-20 | — | — | US | disclosed |
| US-20230365587-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-11-16 | — | — | US | disclosed |
| WO-2023183275-A1 | HEXAHYDROPYRIDO[4,3-B]INDOLYL KETONE DERIVATIVES USEFUL AS CGAS MODULATORS | VENTUS THERAPEUTICS U.S., INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183275-A1 | HEXAHYDROPYRIDO[4,3-B]INDOLYL KETONE DERIVATIVES USEFUL AS CGAS MODULATORS | VENTUS THERAPEUTICS U.S., INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4225762-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023092088-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023092107-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2022076618-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20210403469-A1 | NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-30 | — | — | US | disclosed |
| US-20210403469-A1 | NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-30 | — | — | US | disclosed |
| EP-3877366-A1 | NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074895-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | CDK2, CDK20, CDK2AP1 | ATR 286/4885KDM4E 1754/4885L3MBTL1 2867/4885 |
| US-12612416-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, CLCN2, CLIC1 | ATR 3927/4885KDM4E 4300/4885L3MBTL1 2826/4885 |
| US-20250179079-A1 | HEXAHYDROPYRIDO[4,3-B]INDOLYL KETONE DERIVATIVES USEFUL AS CGAS MODULATORS | CGAS, XDH, NPY1R | ATR 1103/4885KDM4E 1682/4885L3MBTL1 3724/4885 |
| US-20210403469-A1 | NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | IDO1, IDO2, TPH1 | ATR 2873/4885KDM4E 1424/4885L3MBTL1 4387/4885 |
| US-20230365587-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | ATR 4289/4885KDM4E 4161/4885L3MBTL1 4257/4885 |
| US-12065438-B2 | Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, TPH1 | ATR 2635/4885KDM4E 1277/4885L3MBTL1 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.